Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
44 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 29, 2026 | clinicaltrials |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 28, 2026 | clinicaltrials |
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)(TroFuse-007) | recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT06357533 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations(TROPION-Lung10) | recruiting | Phase 3 | 675 | AstraZenecaINDUSTRY | 21 | Sep 23, 2026 | clinicaltrials |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 26 | Sep 18, 2026 | clinicaltrials |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | recruiting | Phase 3 | 3,500 | Merck Sharp & Dohme LLCINDUSTRY | 51 | Sep 17, 2026 | clinicaltrials |
| NCT07396558 | Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain | recruiting | N/A | 180 | Hanoi Medical UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07234929 | Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance With Follow-up Tests After Abnormal Chest X-ray Findings Interpret by Artificial Intelligent | recruiting | N/A | 2,692 | Gia Dinh People HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06535607 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors(eVOLVE-02) | recruiting | Phase 2 | 257 | AstraZenecaINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT07698886 | Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | recruiting | Phase 2 | 70 | KTH BiopharmaINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17) | recruiting | Phase 3 | 400 | AstraZenecaINDUSTRY | 21 | Sep 4, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer(TROPION-Lung14) | recruiting | Phase 3 | 582 | AstraZenecaINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT07394530 | Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS(PPOS-PCOS-IVF) | recruiting | N/A | 400 | Hanoi General Hospital (Vietnam)OTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT06824064 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer(VISTA-1) | recruiting | Phase 2 | 150 | Riboscience, LLC.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT07546565 | Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis(UMC-Colprep) | recruiting | N/A | 74 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06227728 | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.(PTC-IMPACT) | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07239479 | DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy | recruiting | N/A | 40 | Tam Anh Research InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 300 | Polaris GroupINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT07197255 | Transcriptomic Profiling of Cumulus Cells From CAPA-IVM | recruiting | — | 10 | Mỹ Đức HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06398067 | Stress Management Intervention Among Breast and Gynecologic Cancer Patients in Viet Nam | recruiting | N/A | 285 | Boston UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07171970 | IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women(SAIGON-PTC) | recruiting | N/A | 600 | Mỹ Đức HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06087120 | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment(BRAVA) | recruiting | — | 125 | Gene SolutionsINDUSTRY | 2 | Sep 23, 2025 | clinicaltrials |
| NCT06768463 | Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer(CYGAS-GC) | recruiting | N/A | 250 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06167460 | Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06929910 | Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.(GS_ZKM) | recruiting | — | 200 | Gene SolutionsINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05421650 | Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr | recruiting | N/A | 240 | CHA UniversityOTHER | 5 | Apr 9, 2025 | clinicaltrials |
| NCT05344339 | Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer | recruiting | N/A | 320 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06202105 | Comparison of Laparoscopic and Open Total Gastrectomy for Locally Advanced Gastric Cancer(LOTA) | recruiting | N/A | 210 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06589388 | ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer | recruiting | — | 100 | Gene SolutionsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05217407 | Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia(MASTERKEY ASIA) | recruiting | — | 1,000 | National Cancer Center, JapanOTHER_GOV | 7 | Mar 22, 2024 | clinicaltrials |
Data updated 15 hours agoSource updated unknownsource: clinicaltrials